Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03290508 · ClinicalTrials.gov registry record
Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer
A clinical trial, sponsored by Myriad Genetic Laboratories.
- Terminated
- Registry status
- 524
- Enrollment target
NCT03290508: Clinical Trial study, sponsored by Myriad Genetic Laboratories.
NCT03290508 is a clinical trial that was terminated before completion, run by Myriad Genetic Laboratories. The registered enrollment target is 524 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03290508 was terminated before completion, sponsored by Myriad Genetic Laboratories.
- TERMINATED
- Registry status
- 524 participants
- Enrollment target
Study Summary
This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient oncologic outcomes, thereby sparing low-risk patients from unnecessary treatments and associated side-effects.
Primary Outcome
Proportion of patients with low Prolaris scores who are initially treated with active surveillance
Interventions
- DIAGNOSTIC_TEST Prolaris Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 524 participants |
| Start Date | 2017-09-14 |
| Est. Completion | 2022-01-14 |
Why NCT03290508 stopped before completion
NCT03290508 is an observational study that tracks outcomes without assigning an intervention. The registered 524 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Prolaris Testing is the first listed.
NCT03290508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03290508 about?
NCT03290508 is a clinical study titled "Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer". This is a long-term prospective registry study to determine whether Prolaris testing in patients with favorable intermediate risk prostate cancer influences physician management decisions toward conservative treatment in patients with Prolaris low-risk scores without negatively impacting patient onc...
What is the current status of trial NCT03290508?
This trial is currently terminated. The enrollment target is 524 participants. The study started on 2017-09-14. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT03290508?
The interventions under investigation include: Prolaris Testing (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03290508?
This trial is sponsored by Myriad Genetic Laboratories, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
- NCT07158814 · 524 participants · Phase 4
Safety of RSV Preventive Monoclonal Antibody
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI